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Abstract
Background: Anaemia affects 60–80 % of patients admitted to intensive care units (ICUs). Allogeneic red blood cell
(RBC) transfusions remain the mainstay of treatment for anaemia but are associated with risks and are costly. Our
objective was to assess the efficacy and safety of iron supplementation by any route, in anaemic patients in adult ICUs.
Methods: Electronic databases (CENTRAL, MEDLINE, EMBASE) were searched through March 2016 for randomized
controlled trials (RCT)s comparing iron by any route with placebo/no iron. Primary outcomes were red blood cell
transfusions and mean haemoglobin concentration. Secondary outcomes included mortality, infection, ICU and
hospital length of stay, mean difference (MD) in iron biomarkers, health-related quality of life and adverse events.
Results: Five RCTs recruiting 665 patients met the inclusion criteria; intravenous iron was tested in four of the RCTs.
There was no difference in allogeneic RBC transfusion requirements (relative risk 0.87, 95 % confidence interval (CI) 0.70
to 1.07, p = 0.18, five trials) or mean number of RBC units transfused (MD -0.45, 95 % CI -1.34 to 0.43, p = 0.32, two trials)
in patients receiving or not receiving iron. Similarly, there was no difference between groups in haemoglobin at
short-term (up to 10 days) (MD -0.25, 95 % CI -0.79 to 0.28, p = 0.35, three trials) or mid-term follow up (last measured
time point in hospital or end of trial) (MD 0.21, 95 % CI -0.13 to 0.55, p = 0.23, three trials). There was no difference in
secondary outcomes of mortality, in-hospital infection, or length of stay. Risk of bias was generally low although three
trials had high risk of attrition bias; only one trial had low risk of bias across all domains.
Conclusion: Iron supplementation does not reduce RBC transfusion requirements in critically ill adults, but there is
considerable heterogeneity between trials in study design, nature of interventions, and outcomes. Well-designed trials
are needed to investigate the optimal iron dosing regimens and strategies to identify which patients are most likely to
benefit from iron, together with patient-focused outcomes.
Trial registration: PROSPERO International prospective register of systematic reviews CRD42015016627. Registered 2
March 2015.
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Background
Anaemia is common in critically ill patients and is asso-
ciated with adverse outcomes [1, 2]. Observational stud-
ies have shown that anaemia affects 60–80 % of patients
admitted to critical care and is present at critical care
discharge in 75 % of patients [3, 4]. The implementation
of restrictive red cell transfusion policies is likely to
compound the observed high prevalence of anaemia [5].
Allogeneic red blood cell (RBC) transfusion has been the
mainstay of treatment for critical illness anaemia, al-
though studies suggest that patients who receive allogen-
eic RBC transfusion are at increased risk of mortality,
ischaemic complications, delayed wound healing, multi-
organ dysfunction and increased length of stay [6–9].
Interest has now focused on the identification of iron-
deficiency as an aetiological factor contributing to the
anaemia observed in critical illness. However, diagnosis
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of absolute iron-deficiency continues to be challenging
in critical care. Critically ill anaemic patients typically
display the hallmarks of anaemia of inflammation and
iron-restricted erythropoiesis secondary to functional
iron deficiency, absolute iron deficiency or iron seques-
tration [10]. As for other inflammatory conditions,
hepcidin as a key regulator of iron homeostasis is con-
sidered to contribute to this functional iron deficiency in
critically ill patients [10]. Iron supplementation, whether
oral or intravenous (iv), is an effective treatment for pa-
tients with absolute iron deficiency; however, iron is es-
sential for bacterial growth, and exogenous intravenous
iron administration has been reported to be associated
with increased risk of infection, raising significant safety
concerns, particularly in this patient group [11].
To assess current knowledge of the role of iron sup-
plementation in critical care, we performed a systematic
review to evaluate the effect of iron supplementation on
allogeneic RBC transfusion requirements and clinical
outcomes (mortality, quality of life and infection) in this
patient group. The safety of iron supplementation was
also evaluated.
Methods
Study methods were implemented according to a prede-
fined protocol [12].
Study identification
Trials were identified from database searches to 14 March
2016 of CENTRAL (The Cochrane Library Issue 2, 2016),
MEDLINE (1946 onwards), Embase (1974 onwards),
CINAHL (1937 onwards), PubMed (E-publications ahead
of print only), Web of Science (1990 onwards) and the
Transfusion Evidence Library (1950 onwards). We searched
for ongoing trials using the trial registration websites World
Health Organization International Clinical Trials Registry
Platform and ClinicalTrials.gov. We did not restrict our
search for trials by date, language, or publication status.
The full search strategy is shown in Additional file 1.
Eligibility criteria
To be included in this systematic review, the following
criteria had to be met: (1) study design: randomized con-
trolled trials; (2) patients: all patients admitted to any
adult intensive care units (ICUs) or high-dependency
units (HDUs); and (3) intervention: iron supplementa-
tion by any route (enteral, iv, intramuscular) versus pla-
cebo or no iron therapy; co-interventions were only
included if they were present in both/all treatment arms.
Trials including children, pregnant women and patients
with chronic kidney disease were excluded [13, 14].
Study selection and data extraction
Two reviewers (AS, NR) independently screened cita-
tions that met inclusion criteria and extracted data onto
a pre-piloted data collection form. Disagreements were
solved through discussion and if no resolution was
found a third author (SS) adjudicated. Two reviewers
(AS and SS) independently extracted study characteris-
tics and outcomes, including study design, methodology,
patient characteristics, iron supplementation strategies
and outcome data. We sought unclear or missing data
by contacting the authors of the individual trials and
allowing them 28 days to respond.
Study outcomes
The primary outcomes of this systematic review were: (1)
requirement for allogeneic RBC transfusion; (2) mean
number of RBCs transfused; and (3) mean haemoglobin
concentration. Secondary outcomes were: (1) all-cause
mortality; (2) in-hospital infection as defined in individual
trials (e.g. confirmed/suspected diagnosis and antibiotic-
free days); (3) mean ICU length of stay (LOS); (4) mean
hospital LOS; (5) mean measurement of biomarkers of
iron status, e.g. ferritin, erythrocyte zinc protoporphyrin
(eZPP), transferrin saturation (Tsat) and serum iron; (6)
morbidity scales (sequential organ failure assessment
(SOFA) score and multiple organ dysfunction score
(MODS)); and (7) health-related quality of life (HrQoL)
(e.g. SF-36) and serious adverse events defined as “any un-
toward medical occurrence that at any dose results in
death, is life-threatening, requires in-patient hospitalisa-
tion or prolongation of existing hospitalization, or results
in persistent or significant disability/incapacity” [15]. We
defined two time points: (1) short-term (up to 10 days)
and (2) mid-term (the last measured time point in hospital
or end of the trial).
Risk of bias assessment
Study quality was judged using the Cochrane Collabor-
ation tool for assessing risk of bias [16]. We assessed the
following domains for each study: random sequence
generation, allocation concealment, blinding of partici-
pants, personnel and outcome assessors, incomplete out-
come data, selective reporting and other bias such as
financial conflicts of interest. A three-point scale was
used to determine low, high or unclear risk of bias.
Data synthesis
Statistical analyses were performed using Review Manager
[17]. Random effects models were used throughout due to
the likely heterogeneity arising from different iron supple-
mentation strategies used and different ICU settings.
Where possible, continuous variables were reported as
mean difference (MD) with 95 % confidence interval (CI)
at follow-up time points as defined above. For outcomes
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which were deemed likely to be skewed in distribution,
namely number of RBC transfusions and serum ferritin,
reported mean and standard deviation were transformed
to a natural logarithmic scale using the methods of
Higgins et al. [18]. In one study that reported count data
for the number of transfusions [19], raw data values were
log transformed after adding a constant of 0.5 to each
value due to the number of patients who received no
transfusions. Dichotomous variables were reported as rela-
tive risk (RR) with corresponding 95 % CI. Heterogeneity
was assessed using the I2 statistic [20]. In one trial with
two intervention arms, data were pooled across the two
intervention arms and compared with the single control
group for the main analysis [19].
Subgroup and sensitivity analysis
Subgroup analyses were performed if there were at least
two trials with comparable subgroups reporting the pri-
mary outcomes: (1) different iron preparations (enteral vs
intravenous) and (2) use of co-interventions, e.g. erythro-
poietin. Sensitivity analyses for risk of bias were intended
but were not carried out due to the limited number of in-
cluded studies.
Results
Our search identified 894 references. Of these, 32
underwent full-text screening after exclusion by screen-
ing of titles, duplicates and abstracts (see Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) study flow diagram in Fig. 1). Five
studies were included in the final analysis [19, 21–24].
One ongoing trial was identified [25].
Description of included studies
Patient populations, trial interventions and outcomes are
summarised in Table 1. The five studies included a total of
665 randomised participants of whom 368 received iron
and 297 received no iron/placebo. Four trials were carried
out in surgical ICUs (cardiothoracic, trauma, general surgi-
cal, burns and neurosurgical) and one trial was carried out
in a mixed ICU that included medical, surgical and trauma
patients. Two trials compared intravenous iron to intraven-
ous placebo, one trial compared intravenous iron to no
iron (control) and one trial compared oral iron to oral pla-
cebo. A fifth trial included three arms: (1) intravenous iron
and oral placebo, (2) oral iron and intravenous placebo,
and (3) oral and intravenous placebo. Co-interventions
were given in two trials: ascorbic acid, cyanocobalamin and
folic acid [22] or folic acid only [24]. All trials reported dif-
ferent dosing regimens as described in Table 1.
Quality assessment and Risk of Bias
The risk of bias in individual trials is shown in Fig. 2.
Only one trial had low risk of bias in every domain [19].
Three trials reported high levels of attrition of random-
ized participants. In one trial, only participants who re-
ceived all six possible doses of the study drug were
analysed for haemoglobin and other markers of iron sta-
tus (46/75 participants in the intervention groups and
48/75 participants in the control group) [23], in the
second trial, 17 participants in the intervention group
and 7 participants in the control group were excluded
from the final analysis [19] and in the third trial only
patients who had not received a blood transfusion
were analysed [21].
Effect of interventions
Allogeneic red blood cell transfusion
All five trials reported on the number of patients who
received an allogeneic RBC transfusion. In meta-analysis
there was no evidence that iron supplementation to treat
anaemia in critical care patients reduced allogeneic RBC
transfusion requirements (RR 0.88, 95 % CI 0.74 to 1.06;
p = 0.18, I2 = 46 %) (Fig. 3a). In subgroup analysis by
route of administration there was no evidence of an ef-
fect of iron supplementation in patients who received
oral iron or those who received intravenous iron (Fig. 4).
Mean number of RBC units
Only two trials reported the number of RBC units re-
ceived in both groups [19, 24]. After transforming to a
log scale, meta-analysis of these two trials showed no
evidence that iron supplementation reduced the mean
number of allogeneic RBC units transfused (MD -0.45,
95 % CI -1.34 to 0.43, p = 0.32, I2 = 79 %) (Fig. 3b).
Mean difference in haemoglobin concentration
Mean (and standard deviation (SD)) changes in haemoglo-
bin concentration at short-term and mid-term follow-up
time points was reported in three trials [19, 21, 24]. There
was no significant difference in the mean haemoglobin
concentration between patients who received iron and
those who did not, either at short-term (MD -0.25, 95 %
CI -0.79 to 0.28, p = 0.35, I2 = 57 %) (Fig. 3c) or mid-term
follow-up (MD 0.21, 95 % CI -0.13 to 0.55, p = 0.23, I2 =
0 %) (Fig. 3d). In the two trials that did not report mean
and SD, one trial reported no change in haematocrit con-
centration over a period of 28 days in both groups [22]
and the other trial found no significant differences in
haemoglobin concentration between groups at any follow-
up time point over 14 days [23].
In-hospital mortality
Four trials reported in-hospital mortality as an outcome
[21–24]. In meta-analysis there was no difference in the
risk of mortality between patients who received iron
supplementation and those who did not (RR 1.04, 95 %
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CI 0.43 to 2.52; p = 0.92, I2 = 52 %) (Fig. 5a). Causes of
mortality were not reported in any trials.
In-hospital infection
Two studies provided data on infection and antibiotic
usage [22, 23]. There was no evidence of a difference in
the risk of infection in patients who received iron sup-
plementation and those who did not (RR 0.89, 95 % CI
0.74 to 1.08, p = 0.23, I2 = 0 %) (Fig. 5b). Neither study
found a significant difference in mean number of anti-
biotic days between the intervention and control groups
(14 vs. 16 days, p = 0.45; 14 vs. 16 days, p = 0.64).
Length of stay
Three trials reported ICU LOS [22–24] and two trials
additionally reported hospital LOS [22, 23]. One trial re-
ported a significantly longer ICU LOS in the control
group compared to the intervention group (58 +/- 31 vs.
29 +/- 18 days, p < 0.05) [24], whereas two trials found no
difference in ICU LOS (12 vs. 14 days, p = 0.69; 10 vs.
11 days, p = 0.53) [22, 23]. Similarly, these trials found no
differences in hospital LOS (14 vs. 16 days, p = 0.24; 14 vs.
16 days, p = 0.50) [22, 23]. Meta-analysis was not per-
formed as only one trial provided mean and SD values.
Biomarkers of iron status
All trials reported serum ferritin measurements. Three
trials reported mean and SD data [19, 21, 24] which
were log-transformed due to the likely skewing of this
outcome. Iron supplementation was associated with
higher log serum ferritin levels at both short-term (MD
0.41 ng/mL, 95 % CI 0.06 to 0.77, p = 0.02, I2 = 78 %)
(Fig. 5c) and mid-term follow up (MD 0.68 ng/mL, 95 %
CI 0.53 to 0.83, p < 0.00001, I2 = 0 %) (Fig. 5d). In two
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow chart showing the selection of studies in this meta-analysis.
EPO erythropoietin
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Table 1 Characteristics of included studies (n = 5)
Study
Garrido-Martin et al. (2012) [19] Madi-Jebara et al. (2004)
[21]
Pieracci et al. (2009) [22] Pieracci et al. (2014) [23] van Iperen et al. (2000) [24]
Iron No iron Iron No iron Iron No iron Iron No iron Iron No iron
Randomised, n iv 71, oral 73 66 40 40 97 103 75 76 12 12
Analysed n iv 54, oral 53 52 40 40 97 103 75 75 12 12
Age, mean (SD/range) iv 65 (11)
oral 65 (10)
65 (12) 59.1 (9.1) 55.3 (9.5) 55.7 (1.9) 58.2 (1.7) 41.6 (18–83) 40.4 (18–87) 67 (49–89) 69 (45–80)
Male, %: iv 70.3 %
oral 71.7 %
76.9 % 90 % 90 % 50.5 % 46.6 % 77.3 % 60.5 % 66.6 % 66.6 %
ICU setting Cardiothoracic Cardiothoracic General surgical, burns,
neurosurgical
Trauma Mixed (surgical, medical,
neurological, trauma)




to treatment, no preoperative
blood transfusion, able to
complete all study visits as per
protocol, able to provide
written consent
Elective cardiac surgery




>18 years, Hb <13 g.dL-1
prior to enrollment, <
72 hours from hospital
admission, current tolerance
of enteral medication,
expected ICU LOS >5 days
Admitted to ICU with trauma,
Hb <12 g.dL-1, Age >18 years, <
72 hours from ICU admission,
expected ICU LOS >5 days
Hb <11.2 g.dL-1, <12.1 g.dL-1 if
cardiac disease, age >18 years,
expected ICU LOS >7 days,
informed consent from patient
or relative
Exclusion criteria Elective cardiac surgery without
exclusion criteria, fibrinolytic
therapy 48 hours prior to CPB,
impaired renal function
(CrCl <50 mls.min-1), previous
surgery for IE, repeat surgery,
pregnant or lactating, active
gastrointestinal bleeding, B12
deficit, ferropenic anaemia,
asthma or allergy, active
infection, included in another
study, hepatic disease, history of
allergy to iron, unlikely to













use of EPO, pregnancy,
prohibition of RBC transfusion,
imminent death, co-
enrollment in another trial
Active haemorrhage, iron
overload (serum ferritin >
1000 ng.mL-1), conditions






recent (within 30 days) use of
immunosuppression, use of EPO
within 30 days, pregnancy or
lactation, prohibition of RBCs,
imminent death, history of
allergy to iron
Pregnancy, iron deficiency
anaemia (ferritin <50 ug.L-1),
vitamin B12 deficiency (<160
pmol.L-1), recent use of
cytostatics or recent
radiotherapy, life expectancy <
7 days, chronic renal failure,
prior use of EPO
Intervention(s) (1) Iron-hydroxide sucrose
complex, iv (Venofer; Uriach
Laboratory) 3 doses of 100
mg/24 hours during pre-
and post-hospitalisation, and
1 pill/24 hours of oral placebo
during the same period and
during 1 month after discharge
(2) Ferrous fumarate (105 mg of
iron) 1 pill/24 hours orally pre-
and postoperatively and during
i) Iron, iv (Venofer;
Luitpold Pharmaceuticals)
200 mg/day to reach total
iron deficit + s/c placebo (a)
Enteral ferrous sulphate





ascorbic acid 500 mg thrice
daily, cyanocobalamin 1 mg,
folic acid 1 mg
Iron sucrose, iv (Venofer;
Luitpold Pharmaceuticals)
100 mg thrice weekly for up
to 6 doses or until ICU discharge
Iron saccharate, iv (Venofer;
Vifor) 20 mg and iv folic acid











Table 1 Characteristics of included studies (n = 5) (Continued)
1 month after discharge, and
intravenous placebo while
hospitalised
Comparator Oral and iv placebo pre-operatively
and postoperatively following same
protocol.
Placebo - s/c and iv
(0.9 % saline).
Oral placebo, same schedule
as intervention protocol.
Co-intervention: ascorbic acid
500 mg thrice daily,
cyanocobalamin 1 mg, folic
acid 1 mg
Placebo, iv (100 mL of 0.9 %
saline) similar dosing schedule
to intervention
No iron. Co-intervention: folic
acid 1 mg daily
Reported outcomes (follow-up
time points, days)
• Hb concentration (baseline, operating
room entry (day 7), exit operating
room, ICU admission, ICU discharge,
postoperative day10 and day 30
post-hospital hospital discharge)
• Immature reticulocyte fraction,
reticulocyte count, serum ferritin (day
1, postoperative day 10 and day 30
post-hospital discharge)
• RBC transfusion (number of patients
transfused, location of transfusion,
mean number of units)
• Hb concentration (day 0,
day 1–5, day 15, day 30)
• Reticulocyte counts (day
1, day 5, day 15, day 30)




• Difference in Hct (baseline,
days 7, 14, 21 and 28)
(primary outcome)
• Serum iron, serum ferritin,
eZPP (baseline, day 7, day
14, day 21, day 28)
• RBC transfusion




• Adverse outcomes -
gastrointestinal upset
• ICU and hospital LOS
• Mortality
• Number of total doses of
study drug received
• Hb concentration (daily)
• Serum iron, serum ferritin,
serum Tsat, eZPP (baseline,
day 7, day 14)
• RBC transfusions
• Transfusion-free days
• Nosocomial infection and type
• Antibiotic exposure
• ICU and hospital LOS
• Mortality
• Hb concentration (days 0, 7,
14, 21)
• Reticulocyte count, sTfR
(days 0, 7, 14, 21)
• Serum EPO (days 0, 2, 6,
10, 21)
• Serum iron, transferrin,
Tsat, ferritin, eZPP, CRP
(days 0, 10, 21)
• Mean blood loss (day 0–21)
• RBC transfusion (mean




aIn a second intervention arm, patients received intravenous iron and recombinant-human erythropoietin (EPO) (300 IU/kg) subcutaneously (s/c) on day 1; this treatment arm was not included in this review because
the co-intervention was not matched in the control group. bIn a second intervention arm, patients received intravenous iron and EPO alfa (300 IU/kg) s/c on days 1, 3, 5, 7, 9; this treatment arm was not included in this
review because the co-intervention was not matched in the control group. ICU intensive care unit, Hb haemoglobin, Hct haematocrit, Tsat transferrin saturation, sTfR soluble transferrin receptor, eZPP erythrocyte zinc









trials that did not report mean and SD values, in one
trial of oral iron supplementation there was no differ-
ence in serum ferritin between iron and placebo groups
throughout the study period [22] and in one trial of
intravenous iron supplementation there were signifi-
cantly higher serum ferritin levels in the iron group
compared to the placebo group at day 7 (median
808 ng/mL vs. 457 ng/mL, p < 0.01) and day 14 (median
1,046 ng/mL vs. 551.5 ng/mL, p < 0.01) [23].
Three trials reported serum iron and eZPP measure-
ments [22–24], all of which found no significant differ-
ence in concentrations between iron and placebo groups
at any time point. Meta-analysis was precluded by a lack
of reporting of mean and SD values. Two trials reported
Tsat levels – in one trial there was a statistically signifi-
cant increase in Tsat levels at day 7 in the intravenous
iron group when compared to placebo (15 % vs. 11 %,
respectively, p = 0.02) but this was below the normal
range and did not persist through to the end of the study
period [21], whereas in another trial there were no dif-
ferences in Tsat levels throughout the study period [24].
Other secondary outcomes
No trials reported data on morbidity scales, HrQoL scores
or serious adverse events as per the definition above.
Adverse events
Only one trial [22] comparing oral iron to placebo re-
ported adverse effects - namely gastrointestinal upset de-
fined as “nausea, vomiting, abdominal cramping, or
constipation, necessitating discontinuation of the study
drug for any period of time”. The authors found no dif-
ference between the iron and placebo groups (12.4 % vs.
8.7 % respectively, p = 0.62).
Discussion
This systematic review identified five randomised trials
enrolling a total of 665 randomised participants to evalu-
ate the effect of iron as a treatment for anaemia in critical
care. There was no evidence that iron supplementation to
treat anaemia in adult critical care reduced allogeneic
RBC transfusion requirements or increased mean haemo-
globin concentrations, and there was no evidence of an
impact on mortality and length of stay. Serum ferritin
concentrations appeared to be significantly elevated in pa-
tients who receive iron supplementation at both short-
term and mid-term follow up. No studies reported on
HrQoL. However, the available evidence from randomised
trials of iron supplementation in critical care patients is
incomplete, and the confidence intervals for all outcomes
were wide, and these limits could encompass clinically im-
portant differences. Only one trial was graded at low-risk
across all domains.
Across all outcomes the analyses in our review showed
moderate heterogeneity between studies due to differ-
ences in patient population, the intervention and the
intervention dose. The patient populations varied across
all trials - cardiac, general surgical, trauma, neurosurgi-
cal and medical - limiting the external generalizability of
the data. The majority of the patients included were in sur-
gical ICUs. There was widespread variation in the dosing
regimens of iron and methods of administration. The effect
of oral iron may be reduced due to poor absorption in pa-
tients with impaired gastro-intestinal function – particularly
in surgical/trauma patients. Intravenous iron may be more
effective than oral iron in states of inflammation, as it can
bypass the effects of hepcidin, an inhibitor of enteric ab-
sorption [11], but the four trials evaluating intravenous iron
tested different formulations and schedules. Finally, the
follow-up time points in all included studies were relatively
short - the longest duration was up to 42 days, so any po-
tential long-term clinical benefits of iron therapy may have
been missed.
To our knowledge, this is the first systematic review of
iron therapy in adult critical care. Strengths include a
comprehensive literature search repeated at two time
points, duplicate data extraction, and consideration of a
broad range of biochemical and clinical outcomes. A
multicentre, phase IIb, randomised, placebo-controlled
trial in critically ill patients, comparing intravenous iron
Fig. 2 Risk of bias summary showing review authors’ judgements
about each risk of bias item for each included study
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Fig. 3 Effect of iron supplementation, by any route, on primary outcomes a requirement for RBC transfusion, b mean number of RBC units
transfused and mean difference in Hb concentration at c short-term follow-up (upto 10 days) and d medium-term follow-up (last measured time
point in hospital or end of the trial). RBC red blood cell, Hb haemoglobin, CI confidence interval, M-H Mantel-Haenszel test, IV inverse variance
Fig. 4 Subgroup analysis: effect of iron supplementation by either intravenous or oral administration on allogeneic red blood cell transfusion
requirement a oral iron versus no iron, b intravenous iron versus no iron. RBC red blood cell, CI confidence interval, M-H Mantel-Haenszel test
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in addition to standard care with standard care alone is
currently recruiting (ACTRN 12612001249842) [25], and
will be incorporated into updated versions of this review.
Our systematic review should be interpreted alongside
other recent reviews. However, these reviews provide lit-
tle data specific to iron supplementation in critically ill
patients. For example, a recent meta-analysis on the
safety and efficacy of intravenous iron in reducing re-
quirement for allogeneic blood transfusion across all pa-
tient groups suggests iron is effective in reducing the
requirement for allogeneic RBC transfusion and increas-
ing haemoglobin concentration, but this meta-analysis
did not report subgroup analyses in critical care patients.
The apparent benefit of iron reported in this review was
also counterbalanced by an increased risk of infection
[11]. There was no difference, however, in serious ad-
verse events or mortality in those receiving intravenous
iron compared with oral or no iron. Similarly, a system-
atic review [26] investigating the safety and efficacy of
iron therapy (oral and/or intravenous) for the treatment
of anaemia in adults (including critical care patients but
without subgroup analysis) found that both oral and
intravenous iron reduced the need for blood transfusion.
Intravenous iron was more effective at improving
haemoglobin levels and quality of life, but neither route
reduced mortality.
Any potential advantages of iron therapy must be bal-
anced against the risk of adverse events. The risk of in-
fection with use of iron is a significant concern in
critically ill patients. Free iron has been shown to pro-
mote bacterial growth in vitro [27] and a meta-analysis
[11] reported that intravenous iron was associated with a
significant risk of infection. In our review only one trial
reported on adverse events, and two trials reported on
infection outcomes, with no significant differences. The
two trials included in this study that reported infection
outcomes used the same standardized definitions for
nosocomial infection. However, infection is often not an
agreed predefined endpoint in many studies [11], which
can limit the strength of the conclusions.
The characterisation of anaemia in critical care pa-
tients is currently challenging as the tests routinely used
Fig. 5 Effect of iron supplementation, by any route, on secondary outcomes a mortality b in-hospital infection and serum ferritin at c short-term
follow-up and d medium-term follow-up. CI confidence interval, M-H Mantel-Haenszel test, IV inverse variance
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to screen for iron deficiency, such as ferritin and trans-
ferrin, are confounded by the presence of inflammation.
The recent discovery of the hormone hepcidin, a key
regulator of iron metabolism and inhibitor of enteric
iron absorption, has opened up avenues for improved
diagnosis and management of anaemia in patients with
concomitant inflammation such as those with critical ill-
ness [28]. It has been postulated that hepcidin may pro-
vide a better marker of iron deficiency than the routine
biochemical tests in current use, thereby allowing more
precise identification of patients with anaemia who likely
to respond to iron therapy, whether intravenous or oral.
The concept of using serum hepcidin to identify iron defi-
ciency in the context of inflammation has been success-
fully applied to other patient populations where it has also
predicted responsiveness to iron therapy [29, 30]. Whether
this holds true for critically ill patients requires further in-
vestigation. Furthermore, an understanding of the bio-
logical role of hepcidin in iron mobilisation might suggest
that intravenous iron may be more advantageous as part
of a targeted strategy to manage the iron-deficiency com-
ponent of anaemia in critically ill patients, in whom serum
hepcidin would be elevated and oral iron absorption
therefore suppressed.
Conclusion
This review has identified five small trials in a diverse
group of critically ill patients. On the basis of low-
moderate quality evidence, we have shown that there is
no evidence that iron supplementation, either intraven-
ous or enteral, to treat anaemia in critically ill patients
reduces transfusion requirements or the mean number
of RBCs transfused, or increases haemoglobin concen-
tration. However the strength of this conclusion is lim-
ited by heterogeneity between studies and risks of bias.
It is clear that further well-designed prospective studies
in larger numbers of patients, with clinically relevant
outcomes and taking into account many of the limita-
tions identified by this review, are required to under-
stand the role of iron supplementation in critical care.
At present, the findings do not support any specific
strategy for routine administration of iron, by any route,
to treat in patients with anaemia in adult critical care.
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